Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331824 · ClinicalTrials.gov registry record · Phase 2
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
A Phase 2 study, sponsored by Matthew Galsky.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01331824 is a Phase 2 study that was terminated before completion, run by Matthew Galsky. The registered enrollment target is 22 participants.
The verdict
NCT01331824, a Phase 2 study, was terminated before completion, sponsored by Matthew Galsky.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine in subjects with metastatic measurable bladder cancer (or urothelial cancers originating elsewhere in the genitourinary tract) who have progressed on 1 prior chemotherapeutic regimen the objective response rate to treatment with amrubicin. The secondary objectives will be to evaluate progression-free survival, survival at 1 year, and the safety of amrubicin as second-line therapy in patients with metastatic urothelial carcinoma.
Interventions
- DRUG Amrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01331824
The ClinicalTrials.gov registry entry for NCT01331824 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amrubicin is the first listed.
NCT01331824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01331824 about?
NCT01331824 is a clinical study titled "Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma". The primary objective of this study is to determine in subjects with metastatic measurable bladder cancer (or urothelial cancers originating elsewhere in the genitourinary tract) who have progressed on 1 prior chemotherapeutic regimen the objective response rate to treatment with amrubicin. The seco...
What is the current status of trial NCT01331824?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2011-02. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01331824?
The interventions under investigation include: Amrubicin (DRUG).
Who is sponsoring clinical trial NCT01331824?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.